Brian Hilberdink is Senior Vice President, Sales, at Novo Nordisk Inc. since September 1, 2020. He is responsible for leading diabetes and obesity sales and educator team across the country.
Mr. Hilberdink is an accomplished pharmaceutical executive with over 25 years of global and domestic experience at Novo Nordisk developing and executing strategy. During his time leading the diabetes commercial organization, his teams launched the world’s first oral GLP-1 in the U.S. marketplace and helped create increased value within the therapeutic category. Before joining Novo Nordisk Inc. in 2019, he was President of Novo Nordisk Canada. As President he significantly increased investment in Canada, launched several innovative products in the therapy areas of diabetes, obesity and hemophilia, and the company was recognized as one of the country’s top 100 employers.
Prior to his work at Novo Nordisk Canada, Mr. Hilberdink was a Corporate Vice President in Global Marketing for Novo Nordisk A/S in Copenhagen, Denmark, leading the launch of the company’s next generation insulin portfolio. He also has previous experience working at Novo Nordisk in the US, where, from 2003 – 2006, he led several commercial teams during a period of significant growth and investment.
Mr. Hilberdink holds a bachelor’s degree from the Arts & Science faculty at Queen’s University in Canada and has completed extensive executive education at multiple universities.